The clearest and most logical summary yet from Teddyward.To...

First 65 Last

Share
Profile

Follow
sarge17

3,232 Posts.

766

18/03/24

10:21

Post #: 72935413
Share

Originally posted by Teddyward: ↑

Has Cheryl clarified and given you such a statement as to your claim? If niot why not if it is so obvious - why not announce to market?

Any form of nasal flushing is likely to reduce viral load.
your comment "The statistical significance for the cohort under 45 IMO was met before end of trial for most in that cohort" IMO is impossible to come to that conclusion from what has been presented. If they had provided a data table or graph we all may be more aware. If that was the case why did they not provide the graph?

If SPL has the data that would highlight what you are inferring why would they not produce a ASX announcement that shows , in your opinion. that a few laggards didn't complete study and if younger immune system cleared virus quicker ( who would have thought that!!) let alone very early in the study it would have been bloody obvious that viral load across all participants under 45 was low ?

It is not like SPL didn't need good news and they IMO spent significant time post study cutting numbers every way they could to get any positives and you are implying they could have announced a simple explanation that they only missed by a few people and chose not to? This doesn't add up IMO. When I ran numbers with some assumptions as SPL haven't provided graph or data I came to the conclusion that the non compliance or failure of Viraleze must have been significant in under 45 to bias whole study.

IMO this trial was just above bare min to try and keep approval that SPl achieved via IMO backdoor and grandfathered by brexit and why I always had doubts about trial design

Until SPL come clean we will be none the wiser and to think that a new CEO after going hard to get any positive from results would not have also included a simple graph , a few extra words to clarify study missed by small number of laggard participants only in 1 arm not complying or realisation that new strain of covid had higher viral load earlier and had cleared quicker , participants in UK had higher natural resistance by being reinfected every 3 months, etc etc doesn't make sense. Not like SPL doesn't need something positive to announce!

Expand

The clearest and most logical summary yet from Teddyward.

To paraphrase for the usual suspects who have eyes that glaze over reading a post of more than 3 sentences:

Apparently the post-market Viraleze trial results were so outstanding, so remarkably good, so ground-breaking that Starpharma either forget to or declined to communicate this to the market in the ASX announcement.

I think that’s the gist of Teddy’s post.

SPL Price at posting: 12.5¢ Sentiment: None Disclosure: Held
1 Upvote

1 Great analysis

Reply